Mexiletine Dosing for Paramyotonia Congenita
For paramyotonia congenita, initiate mexiletine at 200 mg three times daily (600 mg/day total) in adults, with the option to titrate up to 300 mg three times daily if needed for symptom control.
Adult Dosing
The FDA-approved dosing framework for mexiletine provides the foundation for treatment 1. Start with 200 mg every 8 hours (three times daily) taken with food or antacid to minimize gastrointestinal side effects 1. This initial dose has proven effective in clinical trials for myotonic disorders 2, 3.
Dose Titration Strategy
- Initial dose: 200 mg three times daily (600 mg/day total)
- Titration: If symptoms persist after 2-3 days and the medication is well-tolerated, increase by 50-100 mg increments 1
- Target dose: Most patients achieve satisfactory control at 200-300 mg every 8 hours 1
- Maximum dose: 400 mg three times daily (1200 mg/day), though CNS side effects increase substantially at higher total daily doses 1
The evidence from myotonic dystrophy type 1 trials demonstrates that both 150 mg and 200 mg three times daily are effective and well-tolerated over 7 weeks 2. For non-dystrophic myotonias (which includes paramyotonia congenita), the 200 mg three times daily regimen significantly improved patient-reported stiffness and clinical myotonia measures 3.
Administration Considerations
Always administer with food or antacid to reduce gastrointestinal adverse effects, which are the most common reason for discontinuation (occurring in approximately 40% of patients in controlled trials) 1. Taking the medication at bedtime can minimize dizziness, another frequent side effect 4.
Pediatric Dosing
For children with paramyotonia congenita, no established pediatric dosing exists in guidelines or FDA labeling 1. However, based on the case report of a 3-year-old with paramyotonia congenita who improved after a "six-month mexiletine regimen" 5, the medication can be used in children, though specific dosing was not detailed.
In the absence of established pediatric protocols for paramyotonia congenita, extrapolation from general pediatric mexiletine use suggests starting conservatively and titrating based on response and tolerability. Close monitoring is essential.
Important Monitoring and Safety Considerations
Pre-treatment Screening
- HLA-B*15:02 testing is NOT required for mexiletine (this applies to carbamazepine, an alternative agent) 4
- Baseline ECG to assess QT interval and conduction
- Baseline liver function tests, particularly in patients with hepatic disease 1
Ongoing Monitoring
Mexiletine has a favorable cardiac safety profile compared to other antiarrhythmics. In the myotonic dystrophy trials, no prolongation of PR interval, QTc interval, or QRS duration occurred with either 150 mg or 200 mg three times daily dosing 2. This is reassuring for long-term use.
Patients with severe liver disease or marked right-sided congestive heart failure require lower doses and close monitoring due to reduced hepatic metabolism 1. Renal failure does not typically require dose adjustment 1.
Common Adverse Effects
The most frequent side effects are 1:
- Gastrointestinal: Nausea, vomiting, heartburn (39-40% of patients)
- CNS: Dizziness/lightheadedness (19-26%), tremor (13%), coordination difficulties (10%)
- These are generally dose-related and reversible with dose reduction
Serious adverse events are uncommon. Mexiletine does not depress myocardial function 6, making it safer than many alternatives in patients with cardiac comorbidities.
Alternative Dosing Schedule
A twice-daily (every 12 hours) schedule may be considered for patients who achieve adequate suppression on 300 mg or less every 8 hours 1. The same total daily dose can be divided into two doses (maximum 450 mg every 12 hours) to improve compliance 1. This requires careful monitoring to ensure continued symptom control.
Clinical Context and Alternatives
While mexiletine is the best-studied antimyotonic agent for paramyotonia congenita, lamotrigine represents a viable alternative if mexiletine is unavailable, poorly tolerated, or cost-prohibitive. Lamotrigine demonstrated significant antimyotonic effects in non-dystrophic myotonias with better tolerability and lower cost 7. However, mexiletine remains the evidence-based first choice given the specific data in myotonic disorders 8, 3.
The response to mexiletine in paramyotonia congenita is typically dramatic, with most patients experiencing substantial symptom relief 5, 8. Treatment should be continued long-term as symptoms recur upon discontinuation.